Document is current
Any future updates will be listed below
-
Authors
Aboelella, Nada S. https://orcid.org/0000-0002-9009-9897
Park, Ryan
Tang, Erting https://orcid.org/0000-0001-5348-799X
Asby, Nicholas
Ho, Joshua D.
Pan, Tony
Wang, Sidney
Xie, Lishi
Kline, Justin P.
Riedell, Peter A. https://orcid.org/0000-0003-2719-0580
Huang, Jun https://orcid.org/0000-0003-0271-4384
LaBelle, James L. https://orcid.org/0000-0001-6776-4695
-
Funding
Funding for this research was provided by:
AbbVie
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA014599)
AbbVie and University of Chicago Collaborative University of Chicago Comer Development Board Jill and John Svoboda
- License Information
-
More Information
Article History
Received: 22 March 2025
Revised: 15 January 2026
Accepted: 24 February 2026
First Online: 27 April 2026
Competing interests
: J.P.K. has served as a consultant for BMS, ADC Therapeutics, BeiGene, GenMab, AbbVie, Seagen, Gilead, and received research support from Merck outside the submitted work. P.A.R. has served as a consultant and/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite/Gilead, Pfizer, CVS Caremark, Genmab, BeiGene, Janssen, Pharmacyclics, and Genentech/Roche. Honoraria from Adaptive Biotechnologies. Research support from BMS, Kite Pharma, Novartis, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech/Roche, Cellectis, Cargo Therapeutics, and Tessa Therapeutics. J.L.L. has served as a consultant and/or advisory board member for AbbVie, Pfizer, Vertex, and Newave Pharmaceutical, and received research support from AbbVie, the American Cancer Society, and the Myeloma Solutions Fund outside the submitted work. No disclosures were reported by the other authors.
: >All patients consented to the University of Chicago Institutional Review Board-approved protocols IRB#14-0221-CR009 and IRB #18-0025. All experiments were performed in accordance with relevant guidelines and regulations.
